跳到正文
原文
Medical Xpress·· 2026-10-08精选AI 评分65

BMJ发表瑞典全国研究:孕前接种四价HPV疫苗与早产等不良妊娠结局风险降低相关

HPV vaccination before pregnancy linked to lower risk of preterm birth and other major complications

AI 导读

瑞典一项基于全国登记数据的病例对照研究显示,孕前接种四价HPV疫苗与早产、极早产、胎膜早破及娩出严重小于胎龄儿等不良妊娠结局的几率降低相关,17岁前接种者风险下降更明显。研究纳入2006至2023年间624,713例16至35岁女性的首次单胎分娩,其中92,620例(15%)孕前接种过四价HPV疫苗。作者指出该研究为观察性设计,无法确定因果关系,但认为结果支持HPV疫苗在常规免疫规划中的持续实施。

推荐理由

瑞典全国60余万例首次分娩的病例对照数据,为HPV疫苗与妊娠结局的关联提供了大样本观察性证据。

正文
pregnancy
Credit: Amina Filkins from Pexels

Receiving the human papillomavirus (HPV) vaccine before pregnancy is associated with a lower risk of major pregnancy complications, including preterm birth, with a greater reduction in risk seen among women vaccinated at an earlier age, according to a large Swedish study published by The BMJ.

The findings suggest that the benefits of HPV vaccination may extend beyond cancer prevention to reducing adverse pregnancy outcomes, say the researchers.

HPV is one of the most common sexually transmitted infections. The quadrivalent HPV vaccine targets four types of HPV, including two (HPV types 16 and 18) that are responsible for about 70% of all cervical cancers. Growing evidence indicates that HPV infection and the methods used to treat cervical lesions caused by HPV are linked to an increased risk of pregnancy complications, including preterm birth, so preventing HPV holds potential benefits.

Tracking more than 600,000 first births

To explore this further, researchers in Sweden used data from nationwide Swedish registries to evaluate the association between quadrivalent HPV vaccination before pregnancy and the subsequent risk of adverse pregnancy outcomes.

Their findings are based on 624,713 singleton, first-time births among women ages 16–35 in Sweden between 2006 and 2023, of whom 92,620 (15%) had received quadrivalent human papillomavirus vaccination before pregnancy.

Cases were women with at least one adverse pregnancy outcome, including preterm birth (before 37 weeks), very preterm birth (28 to 31 weeks), preterm and/or prelabor rupture of membranes, delivering a small or severely small baby, stillbirth or newborn death.

Each case was matched with up to 10 control women of the same age and year of conception. A range of other potentially influential factors were taken into account, including self-reported cigarette smoking and body mass index at the first prenatal visit, maternal diagnoses and assisted reproduction, mother's country of birth, family income and education level.

Lower risks with earlier vaccination

After accounting for these factors, quadrivalent HPV vaccination was associated with lower odds of all included adverse pregnancy outcomes compared with no vaccination.

Statistically significant associations were seen for preterm and very preterm birth, spontaneous preterm birth, preterm prelabor rupture of membranes and delivering a severely small baby. Risk reduction was generally more pronounced among women vaccinated before age 17.

Observational findings leave causation uncertain

This is an observational study, so no firm conclusions can be drawn about cause and effect, and the authors acknowledge incomplete information on spontaneous abortions and limited investigation of the underlying clinical pathways. Nor can they rule out the possibility that other unmeasured factors may have affected their results.

However, they say this large study, based on high-quality data with long follow-up in a real-world setting, minimized bias and misclassification, enabling assessment of both common and rare adverse pregnancy outcomes. And results were similar after further analyses, suggesting that they are robust.

As such, they say, "Together with previous research showing the safety of human papillomavirus vaccination during pregnancy, our results suggest that human papillomavirus vaccination is not only safe with respect to pregnancy outcomes but may also confer additional benefits by reducing the risk of adverse events."

"Collectively, this evidence supports the global strategy for human papillomavirus vaccination and its continued implementation in routine immunization programs," they add.

Publication details

Quadrivalent human papillomavirus vaccination before pregnancy and pregnancy outcomes: nationwide, population based case-control study, The BMJ (2026). DOI: 10.1136/bmj-2026-100739

Journal information: British Medical Journal (BMJ)

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: HPV vaccination before pregnancy linked to lower risk of preterm birth and other major complications (2026, October 7) retrieved 7 October 2026 from https://medicalxpress.com/news/2026-10-hpv-vaccination-pregnancy-linked-preterm.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com